I learned that I carry APOE4/4 in December 2024.

Like many people here, I immediately went looking for answers.

What I found was a huge amount of conflicting advice. Different supplements, diets, medications, exercise protocols, sleep tools, and opinions. Most recommendations came without a clear baseline, intervention start date, complete protocol, or repeat measurement.

That made it almost impossible to tell the difference between a promising signal and an isolated anecdote.

So I built Phoenix around a different idea:

>

Today we published our first community-generated research release:

# APOE4: The Beat the Odds Study, Release 001

The cohort includes:

* **476 APOE4 carriers**
* **30,737 biomarker readings**
* **176 observations where an intervention and biomarker moved together in a healthier direction**

The report includes:

* What members tried for their brain health
* What happened to their biomarkers afterward
* Individual before-and-after cases
* The complete recorded protocols behind those cases
* Patterns that appeared across multiple members
* Findings that stayed stable or moved in an unfavorable direction
* The methods, data gaps, and limitations

One member’s LDL fell from **263 to 78 mg/dL in 70 days** while taking ezetimibe and psyllium.

That is an important result.

It does not prove that the same combination will produce the same result for another person.

# What this research can and cannot tell us

This is observational member data, not a randomized clinical trial.

Members sometimes changed several things at once. Follow-up periods varied. Not every person completed repeat bloodwork. Many repeated groups remain small. Diet, weight, medication, adherence, and other factors can affect the same biomarker.

Release 001 therefore cannot prove that an intervention caused a result.

It can show:

* What happened in this cohort
* Where a pattern appeared in more than one member
* Where members appeared to respond differently
* Which ideas deserve more structured testing
* Where the data remains too limited to support a conclusion

We have included the disappointing findings with the same care as the positive ones.

The full report is free and delivered by email: [https://thephoenix.community/research/results](https://thephoenix.community/research/results)

I would value critical feedback, especially from people with research, clinical, or statistical experience:

1. Which conclusions need to be more cautious?
2. How should we handle people who change several interventions at once?
3. What minimum replication count should we require before highlighting a pattern?
4. Which biomarkers and outcomes should Release 002 prioritize?

Disclosure: I founded Phoenix, which is a paid APOE4 community. The report is free. This post is intended to discuss the research, not to provide medical advice.

For carriers who want to track their own response and potentially contribute data to Release 002, the Phoenix assessment is here:

[**https://thephoenix.community/start**](https://thephoenix.community/start)

[Original Research] We analyzed 30,737 biomarker readings from 476 APOE4 carriers. Here is what changed, what did not, and what we still cannot conclude.